Myrexis, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1999-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.myrexis.com
Multiple Dose Study of MPC-6827 in Subjects With Refractory Brain Metastases
Phase 1
Completed
- Conditions
- Brain Neoplasms
- First Posted Date
- 2006-10-31
- Last Posted Date
- 2008-02-13
- Lead Sponsor
- Myrexis Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT00393965
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Open-Label Treatment With MPC-7869 for Patients With Alzheimer's Who Previously Participated in an MPC-7869 Protocol
- First Posted Date
- 2006-09-25
- Last Posted Date
- 2008-08-05
- Lead Sponsor
- Myrexis Inc.
- Target Recruit Count
- 1000
- Registration Number
- NCT00380276
Global Efficacy Study of MPC-7869 to Treat Patients With Alzheimer's
- First Posted Date
- 2006-05-04
- Last Posted Date
- 2008-08-05
- Lead Sponsor
- Myrexis Inc.
- Target Recruit Count
- 800
- Registration Number
- NCT00322036
Efficacy Study of MPC-7869 to Treat Patients With Alzheimer's
- First Posted Date
- 2005-03-16
- Last Posted Date
- 2009-05-05
- Lead Sponsor
- Myrexis Inc.
- Target Recruit Count
- 1600
- Registration Number
- NCT00105547
R-Flurbiprofen in Treating Patients With Localized Prostate Cancer at Risk of Recurrence
Phase 2
- Conditions
- Prostate Cancer
- First Posted Date
- 2003-02-06
- Last Posted Date
- 2013-12-18
- Lead Sponsor
- Myrexis Inc.
- Registration Number
- NCT00045123
- Locations
- 🇺🇸
Decatur Memorial Hospital Cancer Care Institute, Decatur, Illinois, United States
🇺🇸Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
🇺🇸Urological Associates, Incorporated, Columbus, Ohio, United States
© Copyright 2025. All Rights Reserved by MedPath